NFKB2 and colorectal carcinoma: Cumulatively, Rg5, a small‐molecule drug targeting NFKB2, could lead to the disassociation of the NFKB2‐STAT2 complex, thus interfering with the PD‐1/PD‐L1 signaling in CRC.